Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Phase II Trial of CT-322 (BMS-844203) plus Irinotecan in Second-Line Metastatic Colorectal Cancer
2008-006561-89Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metastatic colorectal adenocarcinoma (mCRC) comparing CT-322 plus irinotecan-based chemotherapy with Placebo plus irinotecan-based chemotherapy (2 arms). Primary endpoint: Progression-free survival. Started Apr 2009; status: completed.
02
Drugs
pegdinetanib
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2008-006561-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006561-89.